Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bispecific T-cell engagers, represent a promising therapy class for patients in need of additional treatment options, including those with higher genetic risk and heterogeneity (Kumar et al, 2022). This activity led by Rahul Banerjee, MD, FACP, Assistant Professor in the Division of Medical Oncology at the University of Washington and Fred Hutchinson Cancer Center, will provide strategies for leveraging BCMA-directed therapies for improved patient outcomes in relapsed/refractory multiple myeloma.

TARGET AUDIENCE

Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma (MM).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:
Evaluate the mechanisms of action, efficacy, and safety of BCMA-directed therapies in relapsed/refractory MM
Assess guideline-recommended combination and sequential treatment strategies for relapsed/refractory MM
Identify risk factors for the development of treatment-specific adverse events with different classes of BCMA-directed therapies
Describe mechanisms of drug resistance/loss of response to BCMA-directed therapies
Examine the roles of gene expression profiling, soluble BCMA, and measurable residual disease (MRD) in clinical practice"

Expiration

May 22, 2024

Discipline(s)

Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

1.0 CME

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Rahul Banerjee, MD, FACP
Assistant Professor, Division of Medical Oncology
University of Washington
Fred Hutchinson Cancer Center

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Keywords / Search Terms

i3 Health Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, MM, multiple myeloma, multiply relapsed, refractory, refractory multiple myeloma, therapeutics, treatment, therapies, patients, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map